Initial Treatment and Cost of Care in Pulmonary Hypertension

Slideshow

A new study finds that the first treatment chosen to treat PAH may help mitigate the burden of all-cause cost of care.

Treatment options for PAH are evloving, yet patient prognosis remains poor. PAH also confers a heavy ecomomic burden related to cost of drugs, hospitalizations, and comorobidities. There is research that suggests initial treatment with PAH-specific medications (vs combinations of agents) may decrease healthcare utilization. Could this strategy tranlsate into reduced overall healthcare costs to treat PAH? 

Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.